GERD, Esophagitis, and Barrett’s Esophagus — Clinical Documentation Guide (2026)

🔍 Definition

Gastroesophageal Reflux Disease (GERD) is a chronic digestive condition in which stomach acid and/or bile flows back (refluxes) into the esophagus, causing irritation and symptoms. GERD is defined clinically as reflux sufficient to cause troublesome symptoms or complications, per the Montreal Definition (2006), which remains the foundational framework adopted by the American College of Gastroenterology (ACG).

Reflux Esophagitis is inflammation of the esophageal mucosa caused by prolonged acid exposure — the endoscopic/histologic finding that distinguishes GERD with esophagitis (K21.00/K21.01) from GERD without esophagitis (K21.9). The Los Angeles (LA) Classification grades reflux esophagitis A through D based on mucosal break extent.

Barrett's Esophagus is a metaplastic change in which the normal stratified squamous epithelium of the distal esophagus is replaced by columnar intestinal-type epithelium, a premalignant condition that develops in 10–15% of patients with chronic GERD. The American Gastroenterological Association (AGA) and ACG recognize Barrett's esophagus as the primary precursor to esophageal adenocarcinoma.

🗂️ Alternative Terminology

Clinicians, patients, and coders use varied terminology for these conditions. Understanding equivalences prevents under-coding and query opportunities.

🩺 Signs & Symptoms

GERD and esophagitis present with a range of esophageal (typical) and extra-esophageal (atypical) symptoms. Barrett's esophagus is often asymptomatic, identified on surveillance endoscopy in GERD patients.

• Typical/esophageal: Heartburn (pyrosis) — burning sensation rising from epigastrium to chest; regurgitation — effortless return of gastric contents; dysphagia (with stricture or motility disorder); odynophagia (painful swallowing, more common with severe esophagitis); water brash; belching; nausea
• Atypical/extra-esophageal: Chronic cough; hoarseness/laryngitis; asthma or worsened bronchospasm; globus pharyngeus; dental erosion; chronic sinusitis; non-cardiac chest pain
• Alarm symptoms (require urgent evaluation): Dysphagia, odynophagia, unintentional weight loss, hematemesis/melena, anemia — may indicate malignancy or ulceration; see also ACG GERD Guidelines
• Barrett's esophagus: Often clinically silent; typically discovered during EGD performed for GERD evaluation; patients at highest risk include white males ≥50 years with longstanding GERD, obesity, or tobacco use

Severity grading via Los Angeles Classification: Grade A (one or more mucosal breaks ≤5 mm) → Grade B (mucosal breaks >5 mm, not continuous between mucosal folds) → Grade C (mucosal breaks continuous between ≥2 mucosal folds but <75% of esophageal circumference) → Grade D (≥75% circumference).

🧭 Differential Diagnosis

Multiple conditions can mimic GERD or esophagitis; accurate documentation is essential to support the correct ICD-10-CM code.

📋 Clinical Indicators for Coders/CDI

The following clinical indicators should prompt the coder or CDI specialist to review documentation for specificity and query opportunities:

🦴 Anatomy & Pathophysiology

The esophagus is a muscular tube approximately 25 cm in length, extending from the pharynx to the stomach through the diaphragm. Key anatomical structures in GERD pathophysiology:

• Lower esophageal sphincter (LES): The primary anti-reflux barrier — a tonically contracted smooth muscle segment at the gastroesophageal junction (GEJ). In GERD, LES tone is reduced or transient LES relaxations (TLESRs) are excessive, allowing acid egress. The pathophysiology of TLESRs is mediated via the vagus nerve and cholecystokinin.
• Hiatal hernia: Displacement of the gastric cardia above the diaphragm disrupts the LES-diaphragmatic pinchcock mechanism, a major anatomic contributor to GERD.
• Esophageal mucosal defense: Pre-epithelial (mucus, bicarbonate), epithelial (tight junctions, intracellular buffers), and post-epithelial (blood flow) layers protect against acid injury. Prolonged acid exposure overwhelms these defenses, producing inflammation (esophagitis).
• Metaplastic transformation (Barrett's): Chronic acid (and bile) exposure induces transcriptional reprogramming of stem cells near the squamocolumnar junction (SCJ/Z-line). The resulting columnar intestinal metaplasia expresses CDX2 and MUC2 markers. The progression sequence is: GERD → Barrett's → low-grade dysplasia → high-grade dysplasia → esophageal adenocarcinoma (EAC).
• Eosinophilic esophagitis (EoE) mechanism: Antigen-driven Th2 immune response causing eosinophil recruitment. Key mediators include eotaxin-3, IL-5, and IL-13. Distinct from GERD; coded separately as K20.0.

From a MS-DRG perspective, patients hospitalized for complications of GERD/esophagitis (e.g., GI hemorrhage, aspiration pneumonia) are grouped to DRGs 377–384 (GI hemorrhage) or 177–179 (respiratory with MCC/CC), significantly impacting reimbursement relative to ambulatory GERD management.

💊 Medication Impact / Treatment

Pharmacologic management of GERD and its complications is among the most common drug regimens in primary care and gastroenterology. Documenting the specific agents, dosing, and response is critical for CDI and coding accuracy.

• Proton pump inhibitors (PPIs): First-line therapy for GERD, reflux esophagitis, and Barrett's esophagus management. Standard agents include omeprazole, esomeprazole (Nexium), pantoprazole (Protonix), lansoprazole, dexlansoprazole (Dexilant), rabeprazole. Oral PPIs are dispensed under Medicare Part D. IV pantoprazole (Protonix IV) — billed HCPCS J2930 for inpatient use. The presence of PPI therapy in the medication list supports GERD documentation but does not substitute for provider diagnosis.
• H2 receptor antagonists (H2RAs): Famotidine, cimetidine — used for mild GERD or maintenance; Step-down from PPIs; less effective for esophagitis healing.
• Antacids / Alginates: Symptomatic relief only; OTC (Tums, Maalox, Gaviscon); not separately coded or billed under Medicare Part B.
• Potassium-competitive acid blockers (P-CABs): Vonoprazan (Voquezna) — approved by FDA in 2023; emerging alternative to PPIs; faster onset; Part D covered.
• Prokinetics: Metoclopramide — may improve LES tone and gastric emptying in select GERD patients; associated with tardive dyskinesia risk with long-term use.
• Sucralfate: Mucosal protective agent; used adjunctively in esophagitis or pill esophagitis.
• Biologic therapy for EoE: Dupilumab (Dupixent) — FDA-approved for EoE (K20.0); IL-4/IL-13 antagonist; injectable; Medicare Part B if provider-administered; Part D if self-injected.

Medication-related coding implications: Long-term PPI use may warrant coding of Z79.899 (other long-term drug therapy) when clinically relevant. Aspirin or NSAID use contributing to esophageal injury can be captured with additional Z codes.

Preview ends here. The full guide continues with FY2026 ICD-10-CM code sets, CPT surgical coding, MS-DRG mapping, reimbursement guidance, CDI query templates, and an audit checklist — all available to CCO Members.

← Back to All Clinical Documentation Guides